Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial

Critical Care

the Hepcidane study group¹  Philippe Montravers²  Sigismond Lasocki³  Soizic Gergaud³  Karim Asehnoune⁴  Philippe Seguin⁵  Martine Ferrandiere⁶  Samir Jaber⁷  Nicolas Nagot⁸  Pierre Asfar⁹  Katell Peoc’h^1,10  Thibaud Lefebvre^1,10  Sylvain Lehmann^1,11  Thomas Kerforne^1,12 

[1] ;Département Anesthésie Réanimation, APHP, HUPNSV, CHU Bichat, Université Paris Diderot Sorbonne;Département Anesthésie Réanimation, CHU Angers, Université D’Angers;Département Anesthésie Réanimation, CHU de Nantes, Université de Nantes;Département Anesthésie Réanimation, CHU de Rennes, Université de Rennes;Département Anesthésie Réanimation, CHU de Tours, Université de Tours;Département Anesthésie Réanimation, Université de Montpellier;Département D’information médicale, CHU Montpellier, Université de Montpellier;Département Médecine Intensive Réanimation, CHU Angers, Université D’Angers;INSERM U1149, UFR de Médecine Bichat, Centre de Recherche Sur L’Inflammation, Université de Paris;Laboratoire de Biochimie Protéomique Clinique Et IRMB INSERM, CHU de Montpellier, Université de Montpellier;Service D’anesthésie-réanimation, CHU de Poitiers, Université de Poitiers;

关键词: Critically ill;    Anemia;    Iron deficiency;    Iron (treatment);    Hepcidin;    Mortality;   

DOI  :  10.1186/s13054-020-03430-3

来源: DOAJ

【 摘 要 】

Abstract Background Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes. Methods In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoietin for 20 ≤ hepcidin < 41 μg/l. Control patients were treated according to standard care (hepcidin quantification remained blinded). Primary endpoint was the number of days spent in hospital 90 days after ICU discharge (post-ICU LOS). Secondary endpoints were day 15 anemia, day 30 fatigue, day 90 mortality and 1-year survival. Results Of 405 randomized patients, 399 were analyzed (201 in intervention and 198 in control arm). A total of 220 patients (55%) had ID at discharge (i.e., a hepcidin < 41 μg/l). Primary endpoint was not different (medians (IQR) post-ICU LOS 33(13;90) vs. 33(11;90) days for intervention and control, respectively, median difference − 1(− 3;1) days, p = 0.78). D90 mortality was significantly lower in intervention arm (16(8%) vs 33(16.6%) deaths, absolute risk difference − 8.7 (− 15.1 to − 2.3)%, p = 0.008, OR 95% IC, 0.46, 0.22–0.94, p = 0.035), and one-year survival was improved (p = 0.04). Conclusion Treatment of ID diagnosed according to hepcidin levels did not reduce the post-ICU LOS, but was associated with a significant reduction in D90 mortality and with improved 1-year survival in critically ill patients about to be discharged after a prolonged stay. Trial registration www.clinicaltrial.gov NCT02276690 (October 28, 2014; retrospectively registered)

【 授权许可】

Unknown